During the last month, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) has reported several significant developments and is an opportunity that we are closely following. From forming strategic partnerships to purchasing cannabis biomass to launch a line of cannabis 2.0 products, Pure Extracts has been executing on…
-Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as…
If you have not been following Field Trip Health Ltd. (CSE: FTRP) (OTCQX: FTRPF), you may want to put the company on your radar after it closed a massive private placement. Last week, Field Trip reported to have closed a previously announced $95 million bought deal short form prospectus offering.…
The psychedelic therapy market is one of the most exciting emerging industries and is a vertical that we have been highly focused on. We expect 2021 to be a transformational year for the psychedelic sector as companies prepare to report Phase 3 clinical trial data. We expect positive phase 3…
Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that effective February 16, 2021, it has closed its previously announced financing (see news release February 5, 2021) and issued 3,333,333 million units…
From the easing of regulations to the reporting of positive clinical trial data, the psychedelic sector is a rapidly evolving industry that is starting to show serious signs of legitimacy. We believe the biggest potential catalyst for the psychedelic sector would be the reporting of positive data from Phase 3…
MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body. The trial will be conducted at the University Hospital Basel Liechti Lab, in Basel,…
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that FINRA accepted its proposed symbol change for the OTCQB market from the former DCNPF to PSYCF. The Company's shares have commenced trading in…
Last month, we published an article that highlighted Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) as an attractive play on the cannabis and psychedelic extract market. Our thesis is based off the strength of the management team, the structure of the business, and the potential catalysts for…
In late December, Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) reported to have started to research the impact that muscimol has on a variety of ailments and we are impressed with how the story has advanced since then. Less than two weeks after Psyched announced that it started…
